title: Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model.
abstract: BACKGROUND
  The HPV16 E7 protein is both a tumour-specific and a tumour-rejection antigen, the ideal target for developing therapeutic vaccines for the treatment of HPV16-associated cancer and its precursor lesions. E7, which plays a key role in virus-associated carcinogenesis, contains 98 amino acids and has two finger-type structures which bind a Zn++ ion. The ability of an Escherichia coli-produced E7-preparation, assembled into particles, to induce protective immunity against a HPV16-related tumour in the TC-1-C57BL/6 mouse tumour model, was evaluated.
  
  
  METHODS
  E7 was expressed in E. coli, purified via a one-step denaturing protocol and prepared as a soluble suspension state after dialysis in native buffer. The presence in the E7 preparation of particulate forms was analysed by non-reducing SDS-PAGE and negative staining electron microscopy (EM). The Zn++ ion content was analysed by mass-spectrometry. Ten μg of protein per mouse was administered to groups of animals, once, twice or three times without adjuvant. The E7-specific humoral response was monitored in mice sera using an E7-based ELISA while the cell-mediated immune response was analysed in mice splenocytes with lymphoproliferation and IFN-γ ELISPOT assays. The E7 immunized mice were challenged with TC-1 tumour cells and the tumour growth monitored for two months.
  
  
  RESULTS
  In western blot analysis E7 appears in multimers and high molecular mass oligomers. The EM micrographs show the protein dispersed as aggregates of different shape and size. The protein appears clustered in micro-, nano-aggregates, and structured particles. Mice immunised with this protein preparation show a significant E7-specific humoral and cell-mediated immune response of mixed Th1/Th2 type. The mice are fully protected from the tumour growth after vaccination with three E7-doses of 10 μg without any added adjuvant.
  
  
  CONCLUSIONS
  This report shows that a particulate form of HPV16 E7 is able to induce, without adjuvant, an E7-specific tumour protection in C57BL/6 mice. The protective immunity is sustained by both humoral and cell-mediated immune responses. The E. coli-derived HPV16 E7 assembled in vitro into micro- and nanoparticles represents not only a good substrate for antigen-presenting cell uptake and processing, but also a cost-effective means for the production of a new generation of HPV subunit vaccines.
authors: Department of Infectious Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy.
authors: Linda
authors: L
authors: Petrone
authors: Maria G
authors: MG
authors: Ammendolia
authors: Armando
authors: A
authors: Cesolini
authors: Stefano
authors: S
authors: Caimi
authors: Fabiana
authors: F
authors: Superti
authors: Colomba
authors: C
authors: Giorgi
authors: Paola
authors: P
authors: Di Bonito
references: Expert Rev Vaccines. 2010 Sep;9(9):1095-107
references: 20822351
references: Curr Opin Immunol. 2009 Feb;21(1):98-104
references: 19217269
references: BioDrugs. 2010 Apr 1;24(2):109-29
references: 20199126
references: Virology. 1989 May;170(1):311-5
references: 2541550
references: Open Virol J. 2008;2:15-23
references: 19440460
references: Virology. 2009 Jan 5;383(1):60-8
references: 18996550
references: Mol Cancer Ther. 2008 May;7(5):1329-35
references: 18483320
references: J Virol. 1989 Mar;63(3):1404-7
references: 2536841
references: Nat Rev Immunol. 2009 Oct;9(10):679-91
references: 19763149
references: Virology. 2009 Feb 20;384(2):335-44
references: 19007963
references: Virology. 2009 Dec 5;395(1):45-55
references: 19800648
references: Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):967-78
references: 20074460
references: Biochemistry. 2000 Dec 26;39(51):16033-45
references: 11123931
references: Int J Cancer. 2009 Oct 15;125(8):1902-11
references: 19598264
references: Oncogene. 1996 Jan 4;12(1):213-20
references: 8552395
references: J Transl Med. 2010 Nov 18;8:118
references: 21087493
references: Virology. 1995 Dec 1;214(1):289-93
references: 8525630
references: Cancer Res. 1996 Jan 1;56(1):21-6
references: 8548765
references: J Virol Methods. 1993 Dec 31;45(3):303-18
references: 8106603
references: J Virol. 1993 Jun;67(6):3142-50
references: 8497045
references: Scand J Immunol. 1995 Sep;42(3):317-23
references: 7660065
references: Protein Expr Purif. 2006 Aug;48(2):281-91
references: 16814565
references: Biochemistry. 2006 Jan 24;45(3):657-67
references: 16411741
references: Infect Agent Cancer. 2006 Nov 08;1:6
references: 17150135
references: J Gen Virol. 1994 Feb;75 ( Pt 2):277-81
references: 8113748
references: J Biol Chem. 1992 Apr 5;267(10):6910-5
references: 1551900
references: Vaccine. 2009 Mar 4;27(10):1511-22
references: 19174177
references: Front Biosci. 2008 Jan 01;13:1003-17
references: 17981607
references: Clin Chem. 2005 Oct;51(10):1845-53
references: 16099939
references: J Biol Chem. 1993 Dec 5;268(34):26018-25
references: 8245034
references: Int J Cancer. 2006 Mar 15;118(6):1508-14
references: 16184553
references: Nat Rev Immunol. 2008 Jan;8(1):34-47
references: 18064051
references: Curr Opin Immunol. 2011 Apr;23(2):252-7
references: 21237632
references: Biochemistry. 2002 Aug 20;41(33):10510-8
references: 12173938
references: Cancer Res. 2002 Jul 1;62(13):3654-8
references: 12097270
references: Vaccine. 2009 Mar 18;27(13):1949-56
references: 19368776
references: J Clin Oncol. 2011 May 1;29(13):1785-94
references: 21220591
references: Gene. 1990 Sep 14;93(2):265-70
references: 2172091
references: Virus Genes. 2010 Feb;40(1):1-13
references: 19838783
references: Hum Gene Ther. 2008 Apr;19(4):354-64
references: 18439124
references: J Med Virol. 1998 Mar;54(3):192-5
references: 9515768
references: Biochemistry. 2004 Mar 30;43(12):3310-7
references: 15035602
references: J Biosci. 2009 Dec;34(6):995-1003
references: 20093753
references: J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):104-9
references: 8280701
references: Virology. 1991 Jun;182(2):513-21
references: 1850917